Shattuck Labs price target raised to $11 from $8 at Wedbush

Wedbush raised the firm’s price target on Shattuck Labs (STTK) to $11 from $8 and keeps an Outperform rating on the shares. The firm notes the company reiterated guidance for SL-325 immunogenicity results in Q2 2026, which Wedbush speculates is likely in the next two weeks. The firm looks for low ADA rates in the healthy volunteer data as initial proof of differentiation from TL1A directed competitors, with further support from receptor occupancy results. PK data could also support Q2M or less frequent dosing intervals, competitive with next-gen TL1A candidates, Wedbush adds.